Evidence & regulatory context
- Mechanism
- No ChEMBL entity for the PEDF 29-mer. ClinicalTrials.gov searched: all 8 PEDF records are observational or biomarker studies measuring endogenous PEDF (aqueous humour, vitreous, plasma, skin); no interventional trial administers PEDF or a PEDF-derived peptide as a therapy. Deliberate zero.
- Target
- Not recorded
- Injury models
- Other
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RabbitOtherSprague-Dawley rats; New Zealand White rabbits for tendon cell isolationMale (rats)n = 16 rats randomised to peptide gel or vehicle, with 16 repai…Peri-lesional subcutaneous injection of the loaded gel150 microlitres of alginate gel containing 100 microM 29-merImmediately after injury
Model: Achilles tendon injury created by full-thickness insertion of an 18-gauge needle 1 cm proximal to the calcaneum
The 29-mer expanded resident tendon stem and progenitor cells, produced more organised collagen and raised ultimate tensile stress and Young modulus to about 89% of intact tendon compared with 69% and 61% for vehicle.
Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.